Misrach Mitiku, is Senior Investment Analyst at EOS Funds focusing on the Biotech and Medtech space. Ms. Mitiku has over 15 years of industry experience. Her current responsibilities include performing fundamental business analysis on life sciences and business development for research services companies.
Most recently, she was a Life Sciences Investment Analyst with Maryland Venture Fund (recently acquired by TEDCO Capital Partners) where she was instrumental in screening, evaluating, conducting due diligence and presenting investment theses on seed-stage life sciences companies.
Misrach was Project Manager at the School of Public Health at the University of Maryland, where she was responsible for coordinating and managing multi-million dollar translational research studies for treatment of HIV comorbidity disorders among an urban and low-income minority population.
Prior to the University of Maryland, Misrach was Senior Research Associate at VaxGen, a clinical and manufacturing stage company and participated in the development of Anthrax vaccine for the US government stockpile under Project BioShield, AIDSVAX, SmallPox and SARS vaccines candidates.
Misrach started her career as a Research Associate at Aviron (later acquired by MedImmune and Astra Zenneca) and contributed to the development programs for FluMist®, CMV, PIV3 and RSV vaccine candidates. Ms. Mitiku holds a B.S. in Biochemistry from the University of California Davis and an M.B.A. from the University of Maryland.